discontinuation of marketing of oral forms

Tuesday 21st January 2025 12:38 PM

LThe Novartis Pharma laboratory has decided to stop marketing oral forms within of the EXELON range (rivastigmine – cf. Boxed) :

**Box – Therapeutic indications for EXELON capsule and oral solution**
Symptomatic treatment of mild to moderately severe forms of Alzheimer’s disease (cf. VIDAL Reco “Major neurocognitive disorder”) Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease

Transdermal forms and generics remain available

The two EXELON specialties 4.6 mg/24h and 9.5 mg/24h transdermal patch remain available (CIP 3400930209172 and CIP 3400930209189). They are indicated only in the symptomatic treatment of Alzheimer’s disease.

Generic rivastigmine capsules (Arrow, Biogaran, Viatris and transdermal patch (Arrow, Biogaran, EG Labo, Sandoz, Viatris and Zentiva) also remain available on the French market.

As a reminder, rivastigmine (like other drugs specific to Alzheimer’s disease: donepezil, galantamine, memantine) no longer has a place in the therapeutic strategy for Alzheimer’s disease (cf. Decision of the High Health Authority of 2019).